Clin2
NCT05540288Possibly a fitRecruiting

Nalmefene vs placebo to reduce cravings in behavioral addictions

Behavioural Addiction

Part of Mental health clinical trials.

This study tests whether nalmefene, a non-opioid medicine, can reduce craving episodes in people with behavioral addictions like gambling, food addiction, or sexual addiction. Participants keep tracking cravings weekly, and compare the nalmefene effect against a placebo in addition to their usual care.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
266 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are age 18 or older, and you can give written informed consent
  • You are currently being treated (or starting care) for gambling, food addiction, or sexual addiction at an addiction clinic
  • You can reliably fill out a weekly diary to report your craving episodes
  • In the week before joining, you had at least one craving episode with intensity 4 out of 10 or higher
  • You are able to take study medicine at the time of day when your craving is usually most intense
  • You are on the French social security system (or covered by it)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07325279Recruiting· Phase 1
Nalmefene Implant Safety Study in Healthy Adults

This trial tests a new implant form of the medicine nalmefene to see if it is safe and well-tolerated in healthy adults. It is an early-phase study that helps researchers understand how the body reacts to the implant before testing it in people with opioid use problems.

Morrisville, North Carolina
NCT06845124Recruiting· Phase 2
Testing CBD and naltrexone for alcohol craving

This trial is testing if taking cannabidiol (CBD) plus naltrexone can reduce alcohol craving in people with alcohol dependence. Naltrexone is already used to help with alcohol cravings, and CBD may add extra benefit.

Wiesloch, Baden-Wurttemberg
NCT06622239Not yet recruiting· Phase 2
Naltrexone for reducing self-injury urges

This trial tests a medication called naltrexone to see if it can reduce the urge to hurt yourself. If you have a strong, repeated urge to self-injure, this treatment might help you feel more in control.

Seoul
NCT07734363Recruiting
How Cravings Affect Addiction Severity Over Time

This trial is a longitudinal study that tracks how cravings (strong urges to use) affect a person's addiction over time. It may help researchers understand how cravings lead to more severe addiction, which could improve future treatments.

Bordeaux
NCT07771725Not yet recruiting· Phase 1
Sweeteners and nicotine addiction

This study tests how different sweeteners might affect the addictive properties of nicotine. It may help find ways to reduce nicotine dependence.

West Haven, Connecticut
NCT07641283Not yet recruiting
Naltrexone to reduce self-injury behaviors

This study tests whether naltrexone, a medication that blocks opioid receptors in the brain, can reduce nonsuicidal self-injurious behavior (like cutting or burning). Researchers believe this medication may help decrease the urge to self-injure.

Uijeongbu-si, Gyeonggi-do

Hear when a new Behavioural Addiction trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.